NHS England has announced the creation of a new database aimed at identifying genetic risks associated with cancer, a significant step in enhancing patient care and preventive measures. This initiative will allow tens of thousands of individuals to assess their potential risk of developing cancer through a register of 120 genes known to elevate that risk. The database, expected to be operational as part of a comprehensive 10-year plan, marks a pioneering effort in cancer prevention.
The database will enable individuals, including family members of cancer patients and those currently diagnosed with cancer, to compare their genetic profiles against the registry. This comparison can facilitate earlier screenings and more personalized treatment options. Professor Peter Johnson, the National Clinical Director for Cancer at NHS England, emphasized the importance of this initiative, stating, “We are entering a new era of cancer prevention with pioneering research and testing helping us to discover more about how genes influence our chances of developing cancer.”
This new register, officially named the NHS National Inherited Cancer Predisposition Register, follows the success of the Lynch syndrome register. The latter has effectively identified thousands of individuals diagnosed with Lynch syndrome, providing them with routine preventative screenings. Under the new system, those identified as having an inherited risk of cancer will be automatically included in the register and invited for screenings and routine tests.
Wes Streeting, the Health Secretary, highlighted the implications of cancer statistics, noting that “one in every two people will get cancer in their lifetime.” He stressed that while inherited genetic factors cannot be changed, the information derived from this database can significantly influence preventive measures. Streeting described the initiative as part of broader efforts to modernize the NHS, making it “fit for the 21st century.”
He further stated, “By launching this world-leading genetic register for people with genetic conditions with an increased risk of cancer, we can provide personalized and preventative care sooner. This register won’t just supercharge innovation – it will be life-changing and life-saving.”
The database aims to streamline access to earlier screenings and tailored treatments for thousands of patients. It also has the potential to test whether a patient’s genetic profile makes their cancer more responsive to certain treatments. This could lead to more effective management strategies for individuals based on their genetic makeup.
Claire Rowney, the chief executive of Breast Cancer Now, expressed her support for the initiative, stating, “We are delighted to see the UK Government commit to creating a comprehensive national database for people at an increased risk of cancer.” She emphasized that this development could significantly enhance access to early screenings and risk-reducing treatments for women at higher risk of breast cancer due to genetics or family history.
Rowney also mentioned the importance of ensuring that the database is accessible to all clinicians and that it facilitates cohesive care for those at risk. She reiterated her organization’s commitment to collaborating with researchers and clinical teams to expedite progress in providing effective information, diagnosis, and treatment for those affected.
As this groundbreaking initiative unfolds, the potential for improved cancer detection and treatment through genetic understanding marks a hopeful advancement in healthcare. The establishment of this database not only aims to enhance individual care but also represents a significant stride in the ongoing fight against cancer.
